Botulinum toxin complications in registered and off‐label aesthetic indications

2020 ◽  
Vol 19 (10) ◽  
pp. 2484-2490
Author(s):  
Marina Landau ◽  
Mark S. Nestor ◽  
Ada Trindade Almeida ◽  
Firas Al‐Niaimi
Keyword(s):  

Toxins ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 332 ◽  
Author(s):  
Lauren L. Spiegel ◽  
Jill L. Ostrem ◽  
Ian O. Bledsoe

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.



2019 ◽  
Vol 35 (03) ◽  
pp. 230-238
Author(s):  
Adrian A. Ong ◽  
David A. Sherris

AbstractBotulinum toxin is integral to the practice of facial plastic surgery. Since it was approved by the U.S. Food and Drug Administration for the temporary improvement of glabellar rhytids in 2002, botulinum toxin has achieved a growing number of off-label clinical applications. These include the management of facial rhytids, brow ptosis, excessive gingival display, masseteric hypertrophy, platysmal banding, facial nerve paralysis, hypertrophic scars, and keloids. Many forms of botulinum toxin have been developed, and their safety and efficacy have been thoroughly established. This article will review the aesthetic and functional uses of botulinum toxin as it relates to the field of facial plastic and reconstructive surgery. In addition, the authors will discuss the suggested quantity of units per injection site based on onabotulinumtoxinA.



2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A19.2-A20
Author(s):  
MA Fernandez de Palencia Espinosa ◽  
V Arocas Casañ ◽  
MJ Sánchez Garre ◽  
L Menéndez Naranjo ◽  
MM Galindo Rueda ◽  
...  


2017 ◽  
Vol 3 (1) ◽  
pp. 39-56 ◽  
Author(s):  
Anna Campanati ◽  
Emanuela Martina ◽  
Katia Giuliodori ◽  
Veronica Consales ◽  
Ivan Bobyr ◽  
...  


Toxins ◽  
2013 ◽  
Vol 5 (1) ◽  
pp. 60-72 ◽  
Author(s):  
Claudia Druschel ◽  
Henriette Althuizes ◽  
Julia Funk ◽  
Richard Placzek


2018 ◽  
Vol 20 (2) ◽  
pp. 195-201
Author(s):  
L R Akhmadeeva ◽  
Kh P Derevyanko

The modern view on the application of botulinum toxin type A for the off-label use in neurology and foreign experience analysis are presented. The «off-label» category referred to any prescription of a medication in case of using it for unregistered indications, with product instruction violation or in the presence of contraindications including age restrictions. The sources of information about medicines were the leaflets of manufacturers of medicines and the State Register of Medicines. It is well known that Botulinum toxin type A is a good therapeutic option for treating children with cerebral palsy. Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in medication-overuse headache patients beyond the first year of treatment. Botulinum toxin type A is effective in the management of sialorrhea. Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction. Facing depression with botulinum toxin: positive effects on mood have been observed in subjects who underwent treatment of glabellar frown lines with botulinum toxin and, in an open case series, depression remitted or improved after such a treatment. Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson’s disease with deep brain stimulation. The paper describes the problems associated with the lack of clinical data about the possibility of using botulinum toxin type A in different conditions, emphasizes the need to organize clinical trials and educational programs for neurologists as well as more active implementation of protocols for the treatment of patients.



2021 ◽  
Author(s):  
Kevin Phan ◽  
Shannon Younessi ◽  
Danielle Dubin ◽  
Matthew J. Lin ◽  
Hooman Khorasani
Keyword(s):  


Author(s):  
Margit Juhász ◽  
Anna-Marie Hosking ◽  
Natasha Mesinkovska

Background: Botulinum toxin (BoNT), a bacterially produced neurotoxin, is a mainstay in the dermatologic armamentarium. Although BoNT is commonly used to treated rhytides associated with ageing, it can be employed for a variety of other cosmetic purposes and medical disorders. Objective: In this review, the authors aim to describe the multitude of uses for BoNT in the dermatologic field. Materials and Methods: This manuscript was designed as a retrospective review of the on- and off-label applications of BoNT in dermatology.Results: In addition to treatment of rhytides, BoNT has been shown to decrease rosacea, menopause-associated flushing, and facial sebum production, while improving patient confidence in their appearance. Furthermore, BoNT has been successfully used to treat primary hyperhidrosis, hair loss, aberrant scarring, Raynaud’s phenomenon-associated vasospasm, as well as a variety of skin diseases. Side effects of BoNT include pain or discomfort associated with injections during treatment, bruising, asymmetry, and swelling. Patients are generally satisfied with clinical results after BoNT treatment. Conclusion: Dermatologists should be aware of all on- and off-label applications of BoNT to provide patients with timely and appropriate medical care. Further research must be completed to fully characterise the safety and use of BoNT for off-label purposes.



2015 ◽  
Vol 19 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Ali S. Al-Ghamdi ◽  
Noah Alghanemy ◽  
Hanan Joharji ◽  
Dhafer Al-Qahtani ◽  
Hasan Alghamdi
Keyword(s):  


2020 ◽  
Vol 13 (2) ◽  
pp. 205-207
Author(s):  
Joyce L. Oleszek ◽  
Amy S. Kanallakan ◽  
Aaron J. Powell
Keyword(s):  


Sign in / Sign up

Export Citation Format

Share Document